JP2009523453A - Morinda citrifolia (Yaeyama Aoki) fortified product for administration to animals - Google Patents

Abstract

  Both liquid and dry Morinda citrifolia enriched animal foods are provided. Both include pasteurized fruit purees and other Morinda citrifolia plant products.

Description

  The field of the invention relates to products that can be administered to various animals, and more particularly to products that are fortified with Morinda citrifolia.

  Animal foods designed for domestic animals, livestock or pets are generally and preferably prepared as complete feeds, which are defined as a specific composition, It means that it contains all the essential nutrients and supplements necessary to maintain the health and vitality of this pet. This food composition is balanced in nutrition so that a diet limited to that particular food meets all of the animal's nutritional needs. Typical ingredients in animal food formulations are proteins, carbohydrates, fats, vitamins and minerals. Each of these is present in various weight percentages of a particular formulation or composition sufficient to meet the animal's complete nutritional requirements. In addition, other ingredients may be added depending on the specific needs of the animal for which the food is intended.

  A wide variety of different animal food formulations are commercially available. In the past, the nutrients or ingredients in these formulations are typically not designed to provide specific benefits to the animal as desired or needed. In recent years, however, animal food formulations have been designed with specific objectives in mind. Many animal food formulations currently on the market are specialized for animals of different ages, different breeds, or animals with specific requirements such as obesity, bone loss, weight gain, disease or illness. Are being supplied. Other formulations address various energy requirements between animals. A further segment of the animal food market tends to incorporate differences in ingredient usage or products, thereby making itself more attractive taste or diversity.

  For example, animal foods may be specifically designed as selective COX-2 inhibitors. Eicosanoids are synthesized continuously from fatty acid chains of 20 carbon atoms containing at least three double bonds in the membrane. There are four main classes of eicosanoids: prostaglandins, prostacyclins, thromboxanes and leukotrienes, all of which are mainly made from arachidonic acid. All syntheses except leukotriene require the enzyme cyclooxygenase (COX), which has two different isozymes, constitutive COX-1 and inducible COX-2. Because eicosanoids play an important role in pain, fever and inflammation, these synthetic pathways are the target of many therapeutic drugs. For example, non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, Celeblex® and Vioxx® reduce inflammation by inhibiting COX and blocking the initial oxidation step. Furthermore, inhibition of COX has been linked to many other benefits, such as prevention and treatment of cancer, prevention of preterm birth and / or treatment of Alzheimer's disease.

  In addition to COX, inhibition of cytokines, particularly interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) has proven to have many clinical uses Has been. In general, cytokines are intercellular regulatory proteins that mediate many immunological and biological functions, and in certain diseases, particularly autoimmune diseases, chronic inflammatory diseases, and some leukemia situations, cytokines are Production is deregulated.

  Traditionally, indigenous people in the South Pacific islands have found that ingesting the fruit of Morinda citrifolia, sometimes referred to as “Noni”, provides health benefits to themselves and their animals. It was. Certain animals, such as pigs, are supposed to ingest fruits in their natural state, but most animals have difficulty ingesting and digesting the entire naturally occurring Morinda citrifolia fruit. Due to the strong odor and taste of Morinda citrifolia, many animals do not eat this food and avoid contact with fruits and seeds. Because this fruit has a limited shelf life (lifetime of storage) and is therefore very difficult to transport from the South Pacific, it is impractical to import this fruit for use in animals in North America. In addition, some large animals benefit from eating the whole fruit, while poultry, small animals and fish penetrate the outer layer of the fruit and make substantial contributions from the small amount of fruit they can eat. It is understood that it is difficult to obtain a profit.

  Also, feeding fruit to the animal will cause the feeding area to scatter immediately in the rest of the fruit rot. As a result, some animals can enjoy the benefits of naturally occurring fruits, but the whole fruit is never a food available to livestock.

  High morbidity among young livestock is a problem, which can cause significant financial losses for farmers and farmers. Current methods of controlling morbidity include standard oats or grains for livestock and poultry, inoculations and antibiotics.

  This problem is particularly acute in young cattle (calves). Weaning, treatment and transport of young beef cattle are known to be extremely stressful and often result in high morbidity and mortality. For example, in a 6-year study, over 15% of calves show bovine respiratory disease (BRD), and about 70% of fatal loss in fattening farms is attributed to BRD. However, mortality loss is often not the greatest cost. Weight loss, reduced daily weight gain, torso disassembly, drug costs and torso drug residue can correspond to $ 50.00 to $ 100.00 per head without mortality loss.

  A decrease in the frequency and duration of eating and drinking is a good indicator of morbidity. The dry calf intake of calves during the first 28 days in the fattening farm has been shown to be 32% less in sick calves than their healthy counterparts; Daily weight gain was 0.01 Kg (0.02 lb) compared to a normal weight gain of 0.59 Kg (1.3 lb). Therefore, nutritional interventions must take into account that the most diseased calves are those that are least likely to receive the necessary nutrition through feed top dressing. Don't be.

  Preconditioning calves by vaccination, bunk breaking before weaning and / or prophylactic administration of antibiotics is often affected during the first 2-4 weeks after transport to a new facility Reduces rate and mortality. Farmers are prevented from adopting these practices because they cannot recover the costs associated with preconditioning.

  It is well established that bovine immunity is enhanced if nutrition is good. The general addition of immunostimulatory nutrients such as zinc and vitamin E to the diet for calves provides the essential building blocks for building strong immune defenses. Nevertheless, published studies for nutritional intervention studies are not always clear, which clearly indicates that there was still an unidentified deficiency in the studied formulation.

  Most of the common medical treatments for many of the medical issues discussed above can be associated with serious side effects, so there are few contraindications, treat these diseases and syndromes, and reduce the occurrence of antibiotic resistance Thus, compositions containing natural products and dietary supplements are highly desirable not only to alleviate pain in animals, but also to improve meat quality and human health.

SUMMARY OF THE INVENTION The present invention provides various formulations for administering various Morinda citrifolia enriched products to animals to improve physiological conditions and to ameliorate and / or prevent various diseases. And methods. Accordingly, a preferred embodiment of the present invention provides a Morinda citrifolia enriched product that can be administered to an animal. Some embodiments provide animal products that have significant health benefits.

  One aspect of the present invention is that Indian Mulberry or Morinda citrifolia L. It relates to various methods of inhibiting COX-2, TNF-α, IL-1β, IL-8 and IL-6 using specially processed components of plants.

  Certain embodiments of the present invention include one or more processed Morinda citrifolia components as follows: extracts from Morinda citrifolia leaves, hot water extracts of leaves, processed Morinda citrifolia leaves. Ethanol extract, steamed extract of processed Morinda citrifolia leaves, Morinda citrifolia fruit juice, Morinda citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze-concentrated Morinda citrifolia fruit juice, and Morinda citrifolia fruit juice evaporative concentrate, fresh moly Whole fruit of da Citrifolia, whole dried Morinda citrifolia fruit, powdered or solvent-extracted and enzyme-treated Morinda citrifolia seed, or any other processed Morinda citrifolia seed (ie roasted), Blanching, microwave application, heat treatment, immersion in water or aqueous solutions of various salts or compounds), Morinda citrifolia whole fruit with flowers (blossoms or flowers), leaf extract, leaf juice, and defatted And untreated seed extract.

  These and other features and advantages of the present invention are shown or will become more fully apparent in the following detailed description and in the appended claims. This feature and advantage may be realized and obtained by means of the devices and combinations particularly pointed out in the appended claims. Furthermore, the features and advantages of the invention may be learned from the practice of the invention or may be apparent from the detailed description as set forth herein below.

  Preferred embodiments of the present invention provide a delivery system, method and apparatus for obtaining animal foods comprising Morinda citrifolia puree and other additives such as seed extract, fatty acids and minerals. Examples of these delivery systems include pellets, extruded nuggets, extruded flakes, settled nuggets, delivery as liquids via water or lick tank systems, semi-solid and gelatinous forms, low moisture gels, Low moisture gel pellets, crumble, mash, loose diet, sweet diet, and liquid drenching. The present invention administers these various forms of Morinda citrifolia-enhanced products, either by incorporating the product into a diet typically provided for animals or as a top dressing. Is intended. Other administration methods include colostrum administered to newborn calves immediately after birth, or immersion with Morinda citrifolia enriched product to ameliorate mastitis.

BRIEF DESCRIPTION OF THE DRAWINGS In order to obtain the above and other advantages of the present invention, the invention briefly described above will be further described with reference to specific embodiments thereof illustrated in the accompanying drawings. This will be described in detail. It is understood that these drawings depict only typical embodiments of the invention and are therefore not to be construed as limiting the scope thereof, and the invention shall be construed using the accompanying drawings. More specifically and in detail described and explained:
FIG. 1 is a depiction of a liquid delivery device;
FIG. 2 is a depiction of a solid rick block; and FIG. 3 is a depiction of a delivery system for a solid product such as crumble, pellets, flakes or nuggets.

Detailed Description of Preferred Embodiments The present invention contemplates administering various forms of M. citrifolia with or without additional nutrients. Non-limiting examples of products that can be administered to animals include glycosaminoglycans in addition to Morinda citrifolia, hyaluronic acid in addition to Morinda citrifolia, glucosamine HCl in addition to Morinda citrifolia, Morinda citrifolia Chondroitin sulfate is mentioned in addition to glucosamine sulfate and Morinda citrifolia. Other non-limiting examples of Morinda citrifolia containing formulations that can be administered to animals include essential amino acids in addition to Morinda citrifolia, essential fatty acids in addition to Morinda citrifolia, long chain fatty acids in addition to Morinda citrifolia, Morinda citrifolia plus omega-3 fatty acids, Morinda citrifolia plus omega-6 fatty acids, Morinda citrifolia plus macro minerals, Morinda citrifolia plus micro minerals, Morinda citrifolia plus peptide chains, Morinda In addition to Citrifolia, branched chain amino acids, Morinda citrifolia puree, all noni seeds, Morinda citrifolia puree, all fried noni seeds, Morinda citrifolia puree, In addition to all noni seeds roasted and defatted, Morinda citrifolia puree, noni defatted seeds roasted and split, Morinda citrifolia puree, noni seeds roasted and split, Morinda citrifolia puree Stir-fried noni seeds, Morinda citrifolia puree, stir-fried noni defatted seeds, Morinda citrifolia puree, stir-fried noni defatted seeds, Morinda In addition to citrifolia puree, fried noni seeds, Morinda citrifolia puree, fried extruded noni defatted seeds, and Morinda citrifolia puree, fried and extruded Noni seeds.

1. General Description of Morinda citrifolia L. Plants Morinda citrifolia L. ("Morida citrifolia") Citrifolia (Yaeyamaaoki) plants are shrubs or small trees with a maximum height of 10 m. The leaves are arranged in an oval shape from an ellipse facing each other. Small white flowers are thick, spherical, and contained in a head-shaped mass. The fruit is large, thick and egg-shaped. When ripe, it is milky white but has an unpleasant taste and odor. This plant is native to Southeast Asia and spread quickly from India to a wide area in Eastern Polynesia. It propagates randomly throughout the world and is cultivated in plantations and small individuals. Morinda citrifolia flowers are small, white, 3 to 5 pieces, tubular, fragrant and approximately 1.25 cm long. This flower is composed of many small stones with waxy white or greenish white or yellowish, translucent skin fused to an oval, oval or slightly rounded rugged body. It develops into multiple fruits. This fruit contains “eyes” on its surface, similar to potatoes. The fruit is juicy, bitter, dull yellow or yellowish white and has many reddish-brown, hard, oval-triangular, winged two-cell nuclei, each containing four seeds . When fully ripe, the fruit has a strong odor similar to stale cheese. Although this fruit is eaten as food in some countries, the most common use of Morinda citrifolia plants has traditionally been the basis of red and yellow pigments.

2. Morinda citrifolia leaf processing Morinda citrifolia plant leaves are one potential component of Morinda citrifolia plants that may be present in some compositions of the present invention. For example, some compositions comprise leaf extract and / or leaf juice, as further described herein. Some compositions include leaf serum composed of both leaf extract and fruit juice obtained from Morinda citrifolia plants. Some compositions of the present invention include leaf serum and / or various leaf extracts as incorporated into a dietary supplement (herein “nutraceutical”) Any drug or product designed to improve the health of living organisms such as humans or other animals).

  In one embodiment of the present invention, Morinda citrifolia leaf extract is obtained using the following process. First, relatively dry leaves from the Morinda citrifolia L. plant are collected, cut into small pieces and placed in a grinding device, preferably a hydraulic press, where the small pieces of the leaf are crushed. . In some embodiments, the crushed leaf pieces are then leached using an alcohol, such as ethanol, methanol, ethyl acetate or other alcohol-based derivatives, using methods known in the art. Next, in one embodiment, the alcohol and all alcohol soluble components are extracted from the crushed leaf pieces, leaving a leaf extract, which is then thermally reduced to remove all liquid. except. This resulting dried leaf extract is referred to herein as a “primary leaf extract”.

  In some embodiments of the invention, the primary leaf extract is pasteurized until the extract is at least partially sterilized to destroy undesirable organisms. The primary leaf extract is preferably pasteurized at temperatures ranging from 70 to 80 degrees Celsius and for a time sufficient to destroy unwanted organisms without major chemical alteration of the extract. Pasteurization can also be accomplished according to various radiation techniques or methods.

  In one embodiment of the invention, the pasteurized primary leaf extract is placed in a centrifugal decanter, where it is centrifuged to remove any remaining leaf juice from other substances including chlorophyll. Separate. Once this centrifugation cycle is complete, the leaf extract is in a relatively purified state. The purified leaf extract is then pasteurized again in the same manner as discussed above to obtain a purified primary leaf extract.

Preferably, the primary leaf extract, whether pasteurized and / or purified, is further fractionated into two individual fractions: a dry hexane fraction and an aqueous methanol fraction. This is preferably accomplished via gas chromatography comprising silicon dioxide and CH ₂ Cl ₂ -MeOH components using methods well known in the art. In some embodiments of the invention, the methanol fraction is further fractionated to obtain a secondary methanol fraction. In certain embodiments, the hexane fraction is further fractionated to obtain a secondary hexane fraction.

  One or more leaf extracts containing primary leaf extract, hexane fraction, methanol fraction or any secondary hexane or methanol fraction, combined with fruit juice of Morinda citrifolia plant fruit juice, leaf serum (This process of obtaining fruit juice is further described herein). In some embodiments, leaf serum is packaged and frozen for transport; or it is further incorporated into a dietary supplement as described herein.

3. Morinda citrifolia fruit processing One embodiment of the present invention comprises a composition comprising fruit juice of a Morinda citrifolia plant. Since all Morinda citrifolia fruits are not edible for practical purposes, they must be processed to be palatable for human consumption and included in the composition of the present invention . Processed Morinda citrifolia fruit juice can be prepared by separating seed and skin from ripe Morinda citrifolia fruit juice and pulp; filtering the pulp from this juice; and packaging the juice . Alternatively, rather than packaging the juice, the juice may be immediately placed as an ingredient in another product that has been frozen or pasteurized. In some embodiments of the invention, the juice and pulp may be pureed into a homogenous mixture and mixed with other ingredients. Another process involves lyophilizing the fruit and juice. This fruit and juice can be reconstituted during production of the final juice product. Other processes may include air drying the fruit and juice before being chewed.

  In the presently preferred process for making Morinda citrifolia fruit juice, the fruit is picked by hand or mechanically. The fruit can be harvested when the fruit is at least 1 inch (2-3 cm) and up to 12 inches (24-36 cm) in diameter. The fruit preferably has a color ranging from dark green to yellow-green and white, and a graded color in between. The fruit is thoroughly cleaned after harvesting and before any processing.

  The fruit is matured or aged for 0-14 days, but preferably 2-3 days. The fruit is matured or matured by placing it on the device so that it does not touch the ground. The fruit is preferably covered with a cloth or mesh during ripening, but the fruit may be ripened without being covered. Preparations for further processing of this fruit are colored light, for example light green, light yellow, white or translucent colored light. Fruits are examined for damage or for excessive greenness and firmness. Damaged and hard green fruits are separated from acceptable fruits.

  Mature and aged fruits are preferably placed in plastic lined containers for further processing and transportation. Aged fruit containers can be kept in tubes for 0-30 days, but preferably the fruit containers are kept for 7-14 days prior to processing. The container can be stored under freezing conditions as needed before further processing. The fruit is removed from the storage container and processed manually or by a mechanical separator. The seed and skin are separated from juice and pulp.

  This juice and pulp may be packaged in containers for storage and transport. Alternatively, the juice and pulp may be processed immediately to the final juice product. The container may be stored refrigerated, frozen, or at room temperature. The Morinda citrifolia juice and pulp are preferably mixed in a homogenous mixture, after which they may be mixed with other ingredients such as flavorings, sweeteners, nutritional ingredients, plants and colorants. This final juice product is preferably heated and pasteurized at a minimum temperature of 83 ° C or a maximum of 100 ° C. Another product produced is Morinda citrifolia puree and puree juice, either concentrated or diluted. Puree is essentially the flesh separated from the seed and is different from the fruit juice products described herein.

  The product is filled and sealed in a final container of plastic, glass or another suitable material that is resistant to processing temperatures. This container may be maintained at the filling temperature or rapidly cooled and then placed in a shipping container. The shipping container is preferably packaged with a substance and in a manner that maintains or controls the temperature of the product in the final container.

  The juice and pulp may be further processed by separating the pulp from the juice through a filtration device. The filtration apparatus is preferably, but not limited to, a centrifugal decanter, a screen filter having a size from 1 micron up to 2000 microns, more preferably less than 500 microns, a filter press, a reverse osmosis filtration device, and any other Consists of standard commercial filtration devices. The working filter pressure preferably ranges from 0.1 psig up to about 1000 psig. The flow rate is preferably 0.1 g. p. m. Up to 1000g. p. m, and preferably 5-50 g. p. m. Range. The wet pulp is washed and filtered at least once up to a maximum of 10 times to remove juice from the pump. The resulting pulp extract typically has a fiber content of 10 to 40 weight percent. The resulting pulp extract is preferably pasteurized at a minimum temperature of 83 ° C. and then packed into drums for further processing or made into a high dietary fiber product.

4). Morinda citrifolia seed processing Some Morinda citrifolia compositions of the present invention comprise seeds from Morinda citrifolia plants. In one embodiment of the invention, Morinda citrifolia seeds are processed by pulverizing them into seed powder in a laboratory mill. In some embodiments, the seed powder remains untreated. In certain embodiments, the seed powder is further defatted by immersing and stirring the powder in hexane (preferably 1 hour at room temperature (drug: hexane-ratio 1:10)). This residue is in one embodiment then filtered under reduced pressure, defatted again (preferably for 30 minutes under the same conditions) and again filtered under reduced pressure. This powder may be kept overnight in a fume hood to remove residual hexane.

  Further, in certain embodiments of the present invention, the defatted powder and / or untreated powder is preferably extracted with ethanol 50% (m / m) for 24 hours at room temperature at a 1: 2 drug solvent ratio. Is done.

5). Processing Morinda Citrifolia Oils Certain embodiments of the present invention may include oils extracted from Morinda citrifolia plants. This method for extracting and treating fats was filed on August 27, 1999, and incorporated herein by reference, as US Pat. No. 6,214,351 on April 10, 2001. Published US patent application Ser. No. 09 / 384,785. This Morinda citrifolia oil typically contains a mixture of several different fatty acids as triglycerides, such as fatty acids of palmitic, stearin, olein and linole, and other fatty acids present in lesser amounts. Further, the oil / fat preferably contains an antioxidant for inhibiting the deterioration of the oil / fat. Conventional food grade antioxidants are preferably used.

6). General Considerations for Animal Food Animal food has been further improved in its ability to specifically target and meet the specific requirements of various animals. Several animal food preparations are disclosed in US Patent Application No. 6,737,089, which is hereby incorporated by reference in its entirety.

  The present invention contemplates administering various forms of Morinda citrifolia with additional nutrients. Non-limiting examples of products that can be administered to animals include: Morinda citrifolia plus glycosaminoglycan, Morinda citrifolia plus hyaluronic acid, Morinda citrifolia plus glucosamine HCl, Morinda・ Glucosamine sulfate in addition to citrifolia, and chondroitin sulfate in addition to Morinda citrifolia. Other non-limiting examples of Morinda citrifolia-containing formulations that can be administered to animals include: essential amino acids in addition to Morinda citrifolia, essential fatty acids in addition to Morinda citrifolia, Morinda citrifolia In addition to omega-3 fatty acids, Morinda citrifolia in addition to omega-6 fatty acids, Morinda citrifolia in addition to macro minerals, Morinda citrifolia in addition to micro minerals, Morinda citrifolia In addition to peptide chains, Morinda citrifolia, branched chain amino acids, Morinda citrifolia puree plus all noni seeds, Morinda citrifolia puree, all roasted noni seeds, Morinda citrifolia In addition to puree, all noni seeds roasted and defatted, Morinda citrifolia puree and noni defatted seeds roasted and split, Morinda citrifolia puree and noni seeds roasted and split, Morinda In addition to citrifolia puree, roasted and ground noni seeds, Morinda citrifolia puree and roasted and ground noni defatted seeds, Morinda citrifolia puree, roasted and flaked noni degreased In addition to Morinda citrifolia puree, roasted noni seeds, Morinda citrifolia puree, Morinda citrifolia puree, roasted noni defatted seeds, and Morinda citrifolia puree Noni seeds that were roasted and extruded.

  The present invention contemplates administering various forms of M. citrifolia enriched products. Non-limiting examples of these forms include: pellets, extruded nuggets, extruded flakes, settled nuggets, liquid via water, liquid via lick-tank system, semi-solid, Gels, low moisture gels, and low moisture gel pellets.

  The method of delivery of the Morinda citrifolia-enhanced product can be extremely important. Some non-limiting examples of delivery methods include top dressing diets supplied with Morinda citrifolia products, and adding them to the feeding operation used for newborn calves, with newborns just after birth. Examples include a step including adding a Morinda citrifolia product to colostrum to be administered to cattle, and immersion in a Morinda citrifolia fortified product to ameliorate mastitis in the dairy industry.

  There may be several considerations in assessing what form the administration of the Morinda citrifolia product should take. Some non-limiting examples of such points include: Preference-whether the cow / animal eats this product, recommended intake-what is the appropriate dose, milk scent- In the dairy industry this impairs the scent of milk or is incorporated into the feed-can it be conveniently added to the feed without significantly reducing its effectiveness, and the uniformity of mixing-the appropriate dosage for each animal Can it be mixed in the feed in a uniform and consistent manner to ensure that

  We intend to mix well the Morinda citrifolia fortified product and food consumed by animals. In a non-limiting example, we propose to mix Morinda citrifolia enriched products with cereals and hay. In another non-limiting example, we propose to use a water mediator to eliminate Morinda citrifolia.

7). Compositions and Uses The present invention features compositions and methods for administering various Morinda citrifolia enriched products to animals to improve various physiological conditions. For example, the products of the present invention can be used to enhance immunity against gram-negative bacterial infections. Embodiments of the invention also include methods for introducing Morinda citrifolia compositions internally and / or externally into an animal. Some embodiments of the Morinda citrifolia composition include a variety of different components, each embodiment comprising one or more forms of processed Morinda citrifolia components as described and illustrated herein. Including.

  Certain embodiments of the present invention include one or more processed Morinda citrifolia components as follows: extracts from Morinda citrifolia leaves, hot water extracts of leaves, processed Morinda citrifolia leaves. Ethanol extract, steamed extract of processed Morinda citrifolia leaves, Morinda citrifolia fruit juice, Morinda citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze-concentrated Morinda citrifolia fruit juice, and Morinda citrifolia fruit juice evaporative concentrate, fresh moly Whole fruit of da Citrifolia, dried Morinda citrifolia whole fruit, powdered or solvent extracted and enzyme treated Morinda citrifolia seed, or any other treatment (ie roasting, blanching, microwave) Morinda citrifolia seeds that have been subjected to heat treatment, immersion in water or aqueous solutions of various salts or compounds), Morinda citrifolia whole fruit with flowers (blossoms or flowers), leaf extract, leaf juice, and Degreased and untreated seed extract. The composition of the present invention may also contain various other ingredients. Examples of other ingredients include, but are not limited to: artificial flavors, other natural juices or juice concentrates, such as natural grape juice concentrates or natural blueberry juice concentrates; carrier ingredients; And others as further described herein.

  The present invention contemplates administering various forms of Morinda citrifolia with additional nutrients. Non-limiting examples of products that can be administered to animals include: Morinda citrifolia plus glycosaminoglycan, Morinda citrifolia plus hyaluronic acid, Morinda citrifolia plus glucosamine HCl, Morinda・ Glucosamine sulfate in addition to citrifolia, and chondroitin sulfate in addition to Morinda citrifolia. Other non-limiting examples of Morinda citrifolia-containing formulations that can be administered to animals include: essential amino acids in addition to Morinda citrifolia, essential fatty acids in addition to Morinda citrifolia, Morinda citrifolia In addition to omega-3 fatty acids, Morinda citrifolia in addition to omega-6 fatty acids, Morinda citrifolia in addition to macro minerals, Morinda citrifolia in addition to micro minerals, Morinda citrifolia In addition to peptide chains, Morinda citrifolia, branched chain amino acids, Morinda citrifolia puree plus all noni seeds, Morinda citrifolia puree, fried noni whole seeds, Morinda citrifolia puree Well, all fried nonfat seeds, Morinda citrifolia puree, fried noni fat seeds, Morinda citrifolia puree, fried cracked noni seeds, Morinda citrifolia puree In addition to roasted and ground noni seeds, Morinda citrifolia puree and roasted and ground noni defatted seeds, Morinda citrifolia puree and roasted and flaked noni defatted seeds, In addition to Morinda citrifolia puree, stir-fried noni seeds, Morinda citrifolia puree, stir-fried noni defatted seeds, and Morinda citrifolia puree, stir-extrusion Molded noni seeds.

  Any composition having a leaf extract from Morinda citrifolia leaves may include one or more of the following: primary leaf extract, hexane fraction, methanol fraction, secondary hexane and methanol fraction, Leaf serum or leaf nutritional supplement.

  In certain embodiments of the invention, the active ingredient or compound of the Morinda citrifolia component can be extracted using a variety of procedures and processes generally known in the art. For example, the active ingredient may be isolated and extracted using alcohol or alcoholic solutions such as methanol, ethanol, and ethyl acetate, and other alcoholic derivatives using methods known in the art. . These active ingredients or compounds may be isolated and further fractionated or separated from each other into their constituent parts. Preferably, the compound is separated or isolated to identify and isolate any active ingredient that can function to prevent disease, improve health, or perform other similar functions. It is fractionated. In addition, the compound may be fractionated or separated into its components to identify and isolate any significant or dependent interaction that may provide the same health function just mentioned. Also good.

  Optional ingredients and compositions of Morinda citrifolia may be further incorporated into a dietary supplement (again, “nutraceutical” herein is defined as a living animal such as a human or other animal). Any drug or product designed to improve the health of living organisms). Examples of dietary supplements include, but are not limited to: intravenous products, topical skin products, wound healing products, burn healing and treatment products, emergency products, antibacterial products, bone healing and treatment products, anti-inflammatory products , Eye drops, antifungal products, arthritis treatment products, muscle relaxers, and various dietary supplements and other products as may be further discussed herein.

  The compositions of the present invention, including oral compositions, topical skin solutions, intravenous solutions, and other products or compositions may be formulated in any of a variety of embodiments.

  Oral compositions may take the form of, for example, tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art, and such compositions may contain one or more factors such as sweeteners, flavorings, colorants, and storage. An agent may be included. They may also contain one or more additional ingredients such as vitamins and minerals. Tablets may be manufactured to include one or more Morinda citrifolia ingredients in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents, granulating and disintegrating agents, binders, and lubricants. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over an extended period of time. Also good. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

  Aqueous suspensions can be prepared to contain a Morinda citrifolia component mixed with excipients suitable for the manufacture of aqueous suspensions. Examples of such excipients include, but are not limited to: Suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, tragacanth gum, and gum arabic; Dispersants or wetting agents, such as naturally occurring phospholipid-like lecithins, or condensation products of alkylene oxides and fatty acids, such as polyoxyethylene stearate, or condensation products of ethylene oxide and long chain fatty alcohols , For example, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with fatty acids and partial esters derived from hexitol, such as polyoxyethylene sorbitol monooleate, or ethylene Condensation products of Kishido with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.

  Typical sweeteners include, but are not limited to: corn, sugar radish, sugar cane, which can be chemically or enzymatically converted to a crystalline mass, powder, and / or syrup. Natural sugar from potato, tapioca, or other starch-containing sources. Sweeteners may also include artificial or high intensity sweeteners, some of which include aspartame, sucralose, stevia, saccharin and the like. The concentration of sweetener may be between 0 and 50 percent, more preferably about 1 to 5 percent by weight relative to the weight of the Morinda citrifolia composition.

  Representative flavors include, but are not limited to, artificial and / or natural flavor components that contribute to palatability. The concentration of the flavoring agent may range, for example, from 0 to 15 weight percent of the Morinda citrifolia composition. Coloring agents may include food grade artificial or natural coloring agents having concentrations ranging from 0 to 10% by weight of the Morinda citrifolia composition.

  Representative nutritional components can include vitamins, minerals, trace elements, herbs, plant extracts, bioactive chemicals, and compounds at concentrations of 0-10 weight percent of the Morinda citrifolia composition. Examples of vitamins include, but are not limited to, vitamins A, B1-B12, C, D, E, folic acid, pantothenic acid, biotin and the like. Examples of minerals and trace elements include, but are not limited to, calcium, chromium, copper, cobalt, boron, magnesium, iron, selenium, manganese, molybdenum, potassium, iodo, zinc, phosphorus, and the like. Herbs and plant extracts include, but are not limited to, alfalfa grass, bee pollen, chlorella powder, Dong Quai powder, Echinacea root, Gingko Biloba extract, Horsetail herb, Examples include Indian mulberry, Shitake mushroom, Spirulina seaweed, and grape seed extract. Representative bioactive chemicals include, but are not limited to, caffeine, ephedrine, L-carnitine, creatine, lycopene, and the like.

  Ingredients used in topical skin products include any ingredient that is safe to internalize in the mammalian body and can exist in various forms, such as gels, lotions, creams, ointments, etc. Each including one or more carrier factors. Ingredients or carrier factors incorporated into a composition that is administered systemically (eg, intravenously) may also include any known in the art. In one exemplary embodiment, the Morinda citrifolia composition of the present invention is present in one or more, present in an amount per weight of about 0.01 to 100 weight percent, and preferably 0.01 to 95 weight percent. Contains processed Morinda citrifolia ingredients. Some embodiments of the formulation are encompassed in patent number 6,214,351 issued April 10, 2001, which is incorporated herein in its entirety. However, these compositions are intended as examples only and, therefore, those skilled in the art will recognize other formulations or compositions containing processed Morinda citrifolia products.

  In another exemplary embodiment, the internal composition includes the following ingredients: processed Morinda citrifolia fruit juice or puree juice present in an amount of about 0.1 to 80 weight percent; Processed Morinda citrifolia fat, present in an amount of 20 weight percent; and carrier medium present in an amount of about 20-90 weight percent. Morinda citrifolia puree juice or fruit juice can also be formulated with processed Morinda citrifolia dietary fiber products present in similar concentrations.

  The juice and pulp may be dried using various methods. The juice and pulp mixture may be pasteurized or enzymatically processed prior to drying. The enzyme treatment begins by heating the product to a temperature between 32.9 ° C and 57.2 ° C. It is then treated with either a single enzyme or a combination of enzymes. These enzymes include, but are not limited to, amylase, lipase, protease, cellulase, bromelin and the like. The juice and pulp may also be dried with other ingredients as described above in connection with high dietary fiber products. The typical nutritional profile of dried juice and pulp is 1 to 20 percent moisture, 0.1 to 15 percent protein, 0.1 to 20 percent fiber, and vitamin and mineral content.

  The filtered juice and the water from which the wet pulp has been washed are preferably mixed together. This filtered juice is preferably vacuum evaporated to a 40-70 brix and a moisture of 0.1-80 percent, more preferably 25-75 percent. The resulting concentrated Morinda citrifolia juice may or may not be pasteurized. This juice is not pasteurized in an environment where the sugar content or water activity is low enough to prevent microbial growth. This is packaged for storage, transportation and / or further processing.

  Animal foods have been further improved in their ability to specifically target and meet the specific requirements of various animals. Several animal food preparations are disclosed in US Patent Application No. 6,737,089, which is hereby incorporated by reference in its entirety.

8). Delivery Forms and Systems The present invention contemplates administering various forms of M. citrifolia enriched products. Non-limiting examples of these forms include: pellets, extruded nuggets, extruded flakes, settled nuggets, liquid via water, liquid via lick-tank system, semi-solid, Gels, low moisture gels, and low moisture gel pellets.

Delivery Methods Some non-limiting examples of delivery methods include top dressing supplied with Morinda citrifolia products, which can be converted into dry food normally consumed by the species. On the other hand, there is a step of adding as a liquid, or a step of drying Morinda citrifolia product and grinding it, or adding it in the form of granules or pellets. Liquid Morinda citrifolia products are simply mixed with other liquid foods in the appropriate ratio. Sediment pellets are used for fish and other aquatic animals. The Morinda citrifolia additive is mixed in the food in a uniform and consistent manner in the food, whether liquid or dry, to ensure that each animal obtains the appropriate amount of homogeneous benefits. Is done.

  One method for administering Morinda citrifolia enriched food is to administer large doses of liquid or by “drenching”. Drenching means giving each cow, horse, sheep, and / or other animal one quart or one liter of Morinda citrifolia enriched product through the throat at once.

Dosage Forms The present invention contemplates administering various forms of Morinda citrifolia enriched products. Non-limiting examples of these forms include: pellets, extruded nuggets, extruded flakes, settled nuggets, liquids through water, liquids through lick tank systems, semi-solids, gels, low moisture gels , And low moisture gel pellets.

  The method of delivery of the Morinda citrifolia-enhanced product can be extremely important. Some non-limiting examples of delivery methods include top dressing supplied with Morinda citrifolia products, adding it to the feeding operation used for newborn calves, eg, newborn Examples include adding Morinda citrifolia products to colostrum to be administered to calves and soaking with Morinda citrifolia fortified products to ameliorate mastitis in the dairy industry.

  There may be several considerations in assessing what form the administration of the Morinda citrifolia product should take. Some non-limiting examples of such points include: Preference-whether the cow / animal eats this product, dosage-what is the appropriate dosage, milk aroma-dairy Whether this is detrimental to the flavor of milk in the industry, incorporation into the feed—it can be conveniently added to the feed without significantly reducing its effectiveness, and uniformity of mixing—each animal has the right dosage Can it be mixed into the feed in a uniform and consistent manner to ensure that it can be given?

  We intend to mix Morinda citrifolia fortified products with food consumed by animals. In a non-limiting example, we propose to mix Morinda citrifolia enriched products with cereals and hay. In another non-limiting example, we propose to use a water mediator to eliminate Morinda citrifolia.

  For example, the effect of Morinda citrifolia puree, a product of strengthening Morinda citrifolia for mastitis, is interesting. Using a “drench” with a Morinda citrifolia enriched product, a large dose is administered to affected animals, where non-limiting examples of large doses are more than 2 ounces, 1 quart, 2 quarts , 3 quotes, more than 3 quotes can be given on a regular basis, which is, as a non-limiting example, once every other day, once a day, twice a day, or 1 Mention at least 3 times a day. Since each bovine somatic cell count (SCC) is performed periodically, it can be determined very quickly whether the Morinda citrifolia enriched product has the desired effect. In another non-limiting example, an entire herd or group of animals may be treated as described above to ameliorate or prevent undesired physiological conditions, or to enhance or improve a desired physiological condition. May be.

  Reducing antibiotic use can be achieved by administering various Morinda citrifolia enriched products instead.

  In some experiments, the taste and odor of the Morinda citrifolia fortified product have no effect on the taste or smell of milk from cattle that has been administered the Morinda citrifolia fortified product. It was shown to be pleasant. In addition, successful experiments in treating mastitis by injecting Morinda citrifolia-enhancing products into infected compartments and rubbing Morinda citrifolia-enhancing products into the breast to relieve pain and inflammation have been experimentally demonstrated. Indicated. Further experiments have shown that administration of the Morinda citrifolia enriched product to newborn calves prevents the calves from causing diarrhea. In a non-limiting example, newborn calves were administered 2 ounces twice daily, resulting in a substantial reduction in neonatal calf mortality and substantially improved weight gain.

  The following examples are presented to illustrate various embodiments that have been made or can be made in accordance with the present invention, and are given by way of example only. It should be understood that the following examples do not encompass, consolidate, or cover all of the many types of embodiments of the present invention that can be prepared according to techniques as described herein.

Example 1: Bovine Trial In a trial with 100 dairy calves, 2 ounces of Tahitian Noni puree juice were administered twice a day from birth to weaning compared to no treatment per day There was an increase in body weight by 0.4 kg. Treated calves grew 8% faster than untreated calves. This resulted in a weight advantage of 6.33 pounds at weaning. The average age of weaning was 66 days and the average weight at weaning was 155 pounds. These results were subjected to rigorous statistical analysis and found to be significant at 99.9967% for average daily weight gain and 99.99963% for total weight gain. A 95% rating is generally considered highly significant. Male calves gained weight slightly faster than female calves, but the differences were not statistically significant. Fifty male calves and fifty female calves were randomly assigned to treatment and non-treatment groups at birth. All calves were weighed at birth and again at weaning to obtain the reported results. Calves were fed in a bucket with pasteurized whole milk. A custom-made calf starter concentrate was given freely from day 1.

Example 2: Pig trials Piglets were fed noni puree in gel form in three different trials. In the first trial, 10 litter-derived pigs were identified and divided into 4 groups in a manner that minimized differences due to litter and sex. All of these pigs were derived from genetically similar sows, and all were artificially bred with the same boar to minimize genetic differences.

  Two days before weaning, pigs from Group 2 were forced to feed this gel by inserting a tube into their mouth and delivering 5 cc noni puree gel. No treatment was given to the two control groups. Each group of pigs was weighed at the beginning of the trial and thereafter weekly for 3 weeks. The results are shown below.

  The treated pigs had a total weight gain of 297 pounds compared to the control 202 pounds, a 47% advantage over the treated pigs. This is particularly noticeable. This is because there was concern that handling pigs daily had a negative effect on their weight gain. Treated pigs were handled individually each day, while untreated pigs were simply weighed weekly. If these results can be obtained on a daily basis, this means an advantage of 2.97 pounds per pig.

  In the second trial, 10 litters derived from genetically similar sows and seeded by the same boar were divided into two groups of 5 litters each. Litters on the east side of the delivery house were raised as a first group, and litters on the west side of the delivery house were raised as a second group. Starting at 1 week of age, one group of pigs was forcibly fed noni puree for 10 days, while the other groups received no treatment. Each group was weighed daily. The following is the result.

  98 pigs in this trial died 1 day in the untreated group on day 2 after the start. Pigs in the treated group gained more weight than pigs in the untreated group, but the results were not definitive.

  At the time of weaning, the top 22 pigs in each of the treated and untreated groups were placed in two pens for a third trial, taking into account litters and sex. Pigs in the treatment group continued to be forced to feed 5 cc noni puree per day, and pigs in the untreated group continued to have no treatment. Each group was weighed at the beginning and weekly thereafter. The results are shown below.

  Treated pigs were not as big as the trial number 1 advantage and gained 13.5% more weight than untreated, but still reached 0.86 pounds per pig. The owners reiterated the need to develop a more efficient method of administering this product, noting that treatment group pigs treated daily for 31 days were extremely surprised by the end of the trial. ing. Forced feeding with tubes requires excessive labor and is a disadvantage for pigs as a stress factor.

Example 3: Dairy calf stress test 372 dairy calves participated in a stress trial. These were so-called one-day calves purchased from many dairy farms. 84 calves (58 male calves and 26 female calves) received at the farm on the first day of this trial were inserted into their mouths at the time of pick-up and 15 cc The gel was forcibly fed by pouring noni puree gel behind its tongue. Each cow was given an additional 15 cc when lowered on the farm. Each of these 84 calves was subsequently treated again in the morning and evening for the next 6 days.

  The second group of 135 calves (101 male calves and 34 female calves) received at this farm on the second day of the trial were collected at 15 cc noni puree gel at the time of pickup. At the time of dropping, an additional 15 cc was fed. These 135 cattle were subsequently treated for two more days in the morning and evening.

  The third group of 153 calves (116 male calves and 37 female calves) received on this farm on day 9 of the trial were not treated.

  All calves were given a 2 cc shot of antibacterial vaccine upon arrival at the farm, with or without noni puree.

  Calves were tested daily for signs of illness. Every calf showing clinical signs of diarrhea was noted daily. Medications administered by ranch staff were also recorded for each calf. A few calves seemed too small to sell. These sales were recorded as for all deaths. The recorded information is summarized here.

  Problems due to diarrhea were minimal in calves picked up early (first 2 days), increased significantly in calves picked up during the next 4 days, and then dramatically reduced in the last 6 days .

  In short, short-term treatment with the level of noni puree used in this trial did not reduce any stress in the treated animals. Indeed, 3 days of treatment seemed to increase stress. In effect, this is a good meaning. This is because the treatment itself was stressful. When treatment is applied following the stress of being moved, it has proven to be a formidable obstacle to the calves involved.

  Especially considering the high correlation between health problems and pick-up time, the 7-day treatment proved to be very advantageous compared to the 3-day treatment. There was some visual evidence that calves treated for 7 days were overall better than any other. There were no readily apparent differences in response due to gender.

Example 4: Experiments were conducted to determine whether in vitro trial Morinda citrifolia enriched products in rumen fluid had a detrimental effect on the rumen. This result shows that this product is not only harmful to rumen fermentation, but can also prove to have some significant benefit. Although the addition of Morinda citrifolia extract did not detect a significant effect on rumen fermentation in vitro, some promising results were observed. Although the dry matter disappeared, the total VFA concentrate did not affect this study, and inclusion of the extract had a significant effect on the final product of the fermentation, especially at lower inclusion levels (1% of substrate). Had. This is important. This is because it suggests differences in the energy efficiency of fermentation and potential differences in the utilization of dietary proteins by rumen microorganisms. Ruminal propionic acid products are associated with lower hydrogen production than either acetate or butyrate products. Typically, when the propionate product is enhanced, less methane is produced, resulting in a more efficient use of energy. In addition, propionate can stimulate production in the rumen by acting as a glucose producing substrate. A reduction in the proportion of branched chain VFA suggests a decrease in rumen proteolysis and / or deamination. For most diets, protection of dietary protein from rumen degradation is expected to result in increased efficiency of protein utilization.

Example 5: Preference The inventors administered Morinda citrifolia puree to a group of 4 pigs. We administered one formulation with no additional flavoring and four additional formulations with various levels of peppermint added. The pigs were observed for over 2 hours, but they never showed a tendency to try any version of the product. The pigs sniffed the product slightly but did not try to eat it. The pigs do not like this product and do not eat it themselves. We propose that the solution to this problem is to administer the Morinda citrifolia product as about 1 percent of the daily ration of these pigs. One percent should be very small if the flavor is different in the total feed mixture.

  In addition, we plan to use sugar instead of peppermint for the flavor of Morinda citrifolia products. In addition, we plan to mix the Morinda citrifolia product and carrier, and then combine this carrier with the rest of the feed through the mixing process. For example, if we need to add 1 gallon of noni product (liquid) to 1,000 pounds of feed, we mixed 1 gallon with 100 pounds of a suitable carrier. Alternatively, a 100 pound carrier may then be mixed into a 1,000 pound feed.

  The present inventors have found that it is easy to mix puree into the distribution feed and that there are no problems for the piglet to eat it. In addition, the inventors have mixed Morinda citrifolia products with milk repressor for some piglets so that the piglets in the feeding device can be used in such environments. We observe that eating fortified products is not difficult. Furthermore, the inventors have observed that female pigs consume Morinda citrifolia products without a carrier.

Example 6: A study conducted by poultry trials , as discussed below, indicated that Morinda citrifolia ("Noni") enriched diet was harmless and in weight gain between the treatment and control groups. It was shown that there was a difference of about 3.6%.

  The effectiveness of Noni as a supplement to livestock in intensive production systems has not been previously investigated. A limited experiment in recent years was performed on weaned pigs soaked in 5 ml of liquid noni supplement twice daily at 5-23 kg live weight. This treatment significantly improved pig performance, which stimulated Noni's interest as a potential pig supplement.

  The broiler was chosen because of the rapid initial growth of the broiler. Broilers average 40-41 g a day after birth and increase 3.8 times, 2.6 times, 1.8 times and 1.6 times the weight of the previous week at 1, 2, 3 and 4 weeks of age . Thus, a two-week experiment represents a period of strong growth and regulation for the environment. Under applied conditions, dietary supplements that mitigate the effects of stress factors and / or improve habitability, growth and / or feed efficiency have great marketability. The purpose of this study was to monitor the starting diet of broilers at MORINDA, Inc. It was to evaluate the noni test substance provided by (registered trademark).

Materials and Methods One-day-old chicks were winged, weighed, and assigned to a basket of 8 blocks of 24 wire floors based on initial weight. The breeder unit was maintained in an environmentally controlled room, where 60 m ³ airflow, 18 air exchanges per hour, and a 24-hour light cycle. The chicks were observed twice weekly and the water containers were cleaned and refilled daily. Feed and water were allowed free.

  The chicks were fed with a standard starter diet (control) and a liquid noni supplement added at 1% and 2% to the base diet. This starting diet consists of 58.25% yellow corn, 35% soy meal, 3.4% poultry fat, 1.4% dicalcium phosphate, 1.1% calcium carbonate, 0.25% Of sodium chloride, 0.25% vitamin premix, 0.15% sodium chloride premix, 0.15% DL-methionine and 0.05% micromineral mixture. Because there was no information on the stability of noni supplements, a 150 kg control diet was prepared and a laboratory diet containing noni puree was prepared weekly. Feed consumption, body weight and habitability were measured at 2 weeks of age. Broilers were grown in litter, and the excreta dry matter was measured on days 13-14 since the excretion moisture was important for litter status, bird health and poultry meat quality.

  This experiment consisted of 3 treatments (0, 1 and 2% noni puree) and was randomly assigned to a basket of random full block designs with 8 blocks. Eight to nine baskets became the experimental unit. Body weights at 1 and 14 days of age were individually recorded. This data was subjected to analysis of variance using α = 0.05 and tested for response to test substance dose (0, 1 and 2%) using orthogonal polynomial contrasts. For body weight data, individual values were used to test the effect of treatment with appropriate error terms, excluding variability among birds within each experimental unit. Mean and standard errors are shown in the results section.

result

  No statistically significant (P <0.05) treatment differences were detected in the measured response variables. No abnormalities were observed in birds fed 1% or 2% dietary test substance, and the use of noni dietary supplements did not increase the humidity of the effluent. Even when no statistically significant treatment effect was detected on body weight, a 2% noni diet supplement tended to improve the body weight by 3.6%. The results clearly demonstrated that noni dietary supplements had no detrimental effects on behavior, bird status, moisture excretion, growth and feed efficiency.

  Therefore, according to our study: 1) Noni dietary supplements have no adverse effects when included up to 2% in the diet; and 2) Trends in improving body weight (3.6% (Weight gain) is demonstrated in birds fed with 2% noni diet supplements.

  These experiments and their components exemplify known prior art advances in animal foods, but can be significantly enhanced by the inclusion of Morinda citrifolia as an ingredient. By doing so, these products can provide further benefits and benefits to the intended animal. Since there are different types of animal foods, each containing a composition of significantly different ingredients, the present invention is for animals that can enhance any particular composition or formulation through the addition of Morinda citrifolia dietary fiber. Try to get food. Accordingly, several examples are provided, discussed below, in which Morinda citrifolia dietary fiber has been added to a particular composition of ingredients to make a fortified beneficial animal food.

Example 7: Dairy Cow / Mastitis Trial Proposal The present invention contemplates various trials. A non-limiting example of a proposed trial includes administering Morinda citrifolia enriched products to animals to prevent or reduce mastitis. In one trial, there is a dairy farm that milks about 1000 cows twice or three times a day. At any given time, about 12 animals are clinically suffering from mastitis. In this dairy, clinical mastitis is detected during milking. The milker squirts a small amount of milk from each of the four cows before installing the milking machine. Clinical mastitis appears rapidly in this study. If mastitis is present, remove the milk in a separate can and do not enter the bulk tank with all other milk.

  The farm does not treat infected cattle with antibiotics. Instead, milk each time to dryness and ensure that the milk is tested each time. This dairy farm has a machine in its livestock shed that can check the somatic cell count (SCC) for each milking of each infected cow. Once the SCC falls to the normal range, the cow can again be milked in the bulk system as usual.

  This trial is based on a large dose or “drenching” (“drenching” means that each cow, horse, sheep, and / or other animal is given a 1 quart or 1 liter product of Morinda citrifolia enhancement product through the throat daily. For each treated cow, and then monitoring the SCC for comparison with an untreated infected cow. In addition, this trial plan contemplates randomly dividing the infected group into two groups. Once the bovine mastitis has healed, the cow is returned to the healthy cattle list, and new cases removed from the healthy list are randomly divided and half treated with Morinda citrifolia enriched product. The trial plan contemplates "drenching" with pure water only for animals not treated with the Morinda citrifolia enriched product.

Example 8: Inhibition of COX-2, TNF-α, IL-1β, IL-8 and IL-6 The present invention inhibits COX-2, TNF-α, IL-1β, IL-8 and IL-6 Features compositions and methods for doing so. Embodiments of the invention also include a method of introducing a Morinda citrifolia composition into a mammalian body. Some embodiments of the Morinda citrifolia composition include a variety of different components, each embodiment comprising one or more forms of processed Morinda citrifolia components as taught and described herein.

  Administration of Morinda citrifolia products regulates the expression of cyclooxygenase-2 (COX-2) and other inflammatory cytokines, particularly TNF-α, IL-1β, and IL-6, in foal monocytes Thus, endotoxin (lipopolysaccharide, LPS) -induced inflammatory response can be regulated. A non-limiting example of a Morinda citrifolia product that can be administered is TAHITIIAN NONI® EQUIES ESSENTIALS ™.

  In one exemplary study, newborn foals were enrolled in the study after 24 hours of age and appropriate passive immunity (IgG> 800 mg / dl) was confirmed by the SNAP 1 gG test. The experimental foals (n = 2) were then orally dosed with 60 ml of TAHIITIAN NONI ™ EQUIESESENTIALS ™ twice a day for 60 days. The remaining two foals served as age matched controls. Blood was collected on days 10 and 60 and peripheral monocytes were isolated. Monocytes from each foal were divided into an untreated group and a group stimulated with 1000 mg / ml LPS for 2 hours. Quantitative PCR analysis of mRNA expression of COX-2, TNF-α, IL-1β, IL-8, IL-6 was performed and expressed as mean relative fold (x) to show the control group foal and experimental group pups The changes and values obtained from horses were compared.

  On day 10, foals treated with TAHITIIAN NONI® EQUIES ESSENTIALS ™ were subject to age-related expression of COX-2, TNF-α, IL-1β, IL-8 & IL-6 in LPS-stimulated monocytes. Compared to the matched controls, they were 23x, 10x, 15x, 30x and 35x, respectively, which were dramatically reduced.

  Although not as dramatic as the results on day 10, a similar pattern was observed on day 60. Foals treated with TAHIITIAN NONI® EQUIES ESSENTIALS ™ have COX-2, TNF-α, IL-1β, IL-8 & IL-6 expression in LPS-stimulated monocytes compared to age-matched controls. In comparison, they were reduced by 9x, 180x, 8.5x, 22x and 35x, respectively. Monocytes isolated from foals dosed with TAHITIIAN NONI® EQUIES ESENTIALS ™, when compared to control foals, COX-2, TNF-α, IL-1β, IL- after LPS stimulation The expression of 8 & IL-6 mRNA was significantly reduced. The decrease in the expression of these pro-inflammatory mediators is most pronounced at 10 days of age, suggesting that TAHITIIAN NONI® EQUIESESENTIALS ™ may be a promising new anti-inflammatory treatment. It deserves further consideration for its clinical use.

  The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing detailed description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

FIG. 1 is a depiction of a liquid delivery device. FIG. 2 is a depiction of a solid lick block. FIG. 3 is a depiction of a delivery system for a solid product such as crumble, pellets, flakes or nuggets.

Claims (25)

0.01% -30% pasteurized Morinda citrifolia fruit puree;
70% -99% dry food; and essential amino acids in addition to Morinda citrifolia, essential fatty acids in addition to Morinda citrifolia, long chain fatty acids in addition to Morinda citrifolia, omega-3 fatty acids in addition to Morinda citrifolia, Morinda In addition to citrifolia, omega-6 fatty acids, Morinda citrifolia plus macro minerals, Morinda citrifolia plus micro minerals, Morinda citrifolia plus peptide chains, Morinda citrifolia plus branched chain amino acids, Morinda In addition to Citrifolia puree, all noni seeds, Morinda citrifolia puree, all roasted noni seeds, Morinda citrifolia puree, roasted and defatted noni seeds, Morinda citrifolia puree Noni defatted seeds, fried and cracked, Morinda citrifolia puree, noni seeds, fried and cracked, Morinda citrifolia puree, stir-fried noni seeds, Morinda citrifolia puree, stir-fried in addition to Morinda citrifolia puree Noni defatted seeds, Morinda citrifolia puree, stir-fried noni seeds, Morinda citrifolia puree, stir-fried noni seeds, Morinda citrifolia puree Non-fat seeds extruded and extruded, Morinda citrifolia puree in addition to fried extruded noni seeds and Morinda citrifolia puree in addition to fried and extruded noni seed extracts Dry-type additive containing Rumble animal food. Morinda citrifolia leaf extract, leaf hot water extract, processed Morinda citrifolia leaf ethanol extract, processed Morinda citrifolia leaf steam distilled extract, Morinda citrifolia fruit juice, Morinda Citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze-concentrated Morinda citrifolia fruit juice, and Morinda citrifolia Fruit juice evaporative concentrate, fresh Morinda citrifolia whole fruit, dried Morinda citrifolia whole fruit, solvent extracted form Morinda citrif Morinda citrifolia seed treated with enzyme, Morinda citrifolia seed treated with enzyme, whole Morinda citrifolia seed processed, Morinda citrifolia whole fruit, leaf extract, leaf juice, defatted Morinda citrifolia seed extract and untreated Morinda citrifolia 2. The food product of claim 1 comprising a component selected from a list of seed extracts. Furthermore, glycosaminoglycan, hyaluronic acid, glucosamine HCl, glucosamine sulfate, chondroitin sulfate, essential amino acids, essential fatty acids, long chain fatty acids, omega-3 fatty acids, omega-6 fatty acids, macro minerals, micro minerals, peptide chains, branches Chain amino acids, all noni seeds, all fried noni seeds, all fried noni seeds, fried noni nonfat seeds, fried noni seeds, fried noni seeds, fried ground noni seeds, Of roasted and ground noni defatted seeds, roasted and flakes of noni defatted seeds, roasted and flakes of noni seeds, roasted and extruded noni defatted seeds, and roasted and extruded noni of noni The food according to claim 1, comprising an ingredient selected from a list of seeds. Furthermore, quercetin, rutin, scopoletin, octoate, potassium, vitamin C, terpenoid, alkaloid, anthraquinone, nordamanacantal, molindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycoside, linoleic acid, alizarin, amino acid, The food according to claim 1, comprising an active ingredient selected from the group comprising akbin, L-asperloside, caproic acid, caprylic acid, ursolic acid, and putative prozeroin. 4. The food product of claim 3, wherein the quercetin is present in an amount of about 0.1-10% by weight. 4. The food product of claim 3, wherein the rutin is present in an amount of about 0.1-10% by weight. 0.01% -30% pasteurized Morinda citrifolia fruit puree;
20% -90% liquid animal foods; and essential amino acids in addition to Morinda citrifolia, essential fatty acids in addition to Morinda citrifolia, long chain fatty acids in addition to Morinda citrifolia, omega-3 fatty acids in addition to Morinda citrifolia, Morinda citrifolia plus omega-6 fatty acids, Morinda citrifolia plus macro minerals, Morinda citrifolia plus micro minerals, Morinda citrifolia plus peptide chains, Morinda citrifolia plus branched chain amino acids, Morinda・ In addition to citrifolia puree, all noni seeds, Morinda citrifolia puree, all roasted noni seeds, Morinda citrifolia puree, roasted and defatted all noni seeds, added to Morinda citrifolia puree Noni defatted seeds fried and fried, Morinda citrifolia puree, noni seeds fried and fried, Morinda citrifolia puree, fried and ground noni seeds, Morinda citrifolia puree and fried In addition to ground noni defatted seeds, Morinda citrifolia puree, fried noni defatted seeds, Morinda citrifolia puree, fried noni seeds, Morinda citrifolia puree A liquid animal food comprising an additive selected from the list consisting of roasted and extruded noni defatted seeds and Morinda citrifolia puree plus roasted and extruded noni seeds. Morinda citrifolia leaf extract, leaf hot water extract, processed Morinda citrifolia leaf ethanol extract, processed Morinda citrifolia leaf steam distilled extract, Morinda citrifolia fruit juice, Morinda Citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze-concentrated Morinda citrifolia fruit juice, and Morinda citrifolia Fruit juice evaporative concentrate, fresh Morinda citrifolia whole fruit, dried Morinda citrifolia whole fruit, solvent extracted form Morinda citrif Morinda citrifolia seed treated with enzyme, Morinda citrifolia seed treated with enzyme, whole Morinda citrifolia seed processed, Morinda citrifolia whole fruit, leaf extract, leaf juice, defatted Morinda citrifolia seed extract and untreated Morinda citrifolia The food of claim 6, comprising a component selected from a list of seed extracts. Furthermore, glycosaminoglycan, hyaluronic acid, glucosamine HCl, glucosamine sulfate, chondroitin sulfate, essential amino acids, essential fatty acids, long chain fatty acids, omega-3 fatty acids, omega-6 fatty acids, macro minerals, micro minerals, peptide chains, branches Chain amino acids, all noni seeds, all fried noni seeds, all fried noni seeds, fried noni nonfat seeds, fried noni seeds, fried noni seeds, fried ground noni seeds, Of roasted and ground noni defatted seeds, roasted and flakes of noni defatted seeds, roasted and flakes of noni seeds, roasted and extruded noni defatted seeds, and roasted and extruded noni of noni 7. A food product according to claim 6, comprising a component selected from a list of seeds. Quercetin, rutin, scopoletin, octoate, potassium, vitamin C, terpenoid, alkaloid, anthraquinone, nordamanacantal, molindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycoside, linoleic acid, alizarin, amino acid, acvin, The preparation according to claim 6, comprising an active ingredient selected from the group comprising L-asperloside, caproic acid, caprylic acid, ursolic acid, and putative prozeroin. 10. The food product of claim 9, wherein the quercetin is present in an amount of about 0.1-10% by weight. 10. The food product of claim 9, wherein the rutin is present in an amount of about 0.1-10% by weight. Pellets, extruded nuggets, extruded flakes, settled nuggets, delivery as liquids via water or lick tank systems, semi-solid and gelatinous forms, low moisture gels, low moisture gel pellets, crumbles, mashes, loose diets, and Dry food based on Morinda citrifolia, including pasteurized Morinda citrifolia fruit puree mixed with dry animal foods and additives having a form selected from the list consisting of sweet foods. Furthermore, essential amino acids in addition to Morinda citrifolia, essential fatty acids in addition to Morinda citrifolia, long chain fatty acids in addition to Morinda citrifolia, omega-3 fatty acids in addition to Morinda citrifolia, omega-6 in addition to Morinda citrifolia Fatty acids, Morinda citrifolia plus macro minerals, Morinda citrifolia plus micro minerals, Morinda citrifolia plus peptide chains, Morinda citrifolia plus branched chain amino acids, Morinda citrifolia puree plus Noni Seeds, all Morinda citrifolia puree and roasted noni seeds, Morinda citrifolia puree and all roasted noni seeds, Morinda citrifolia puree and roasted and split noni degreased Morinda citrifolia puree and roasted noni seeds, Morinda citrifolia puree and roasted and ground noni seeds, Morinda citrifolia puree and roasted and ground noni defatted seeds, Noni defatted noni defatted seeds fried in addition to Morinda citrifolia puree, noni sautéed noni seeds fried in addition to Morinda citrifolia puree, noni defatted fried exfoliated in addition to Morinda citrifolia puree 13. A food product according to claim 12, comprising an additive selected from the list consisting of edible seeds and Morinda citrifolia puree and roasted extruded noni seeds. Morinda citrifolia leaf extract, leaf hot water extract, processed Morinda citrifolia leaf ethanol extract, processed Morinda citrifolia leaf steam distilled extract, Morinda citrifolia fruit juice, Morinda Citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze-concentrated Morinda citrifolia fruit juice, and Morinda citrifolia Fruit juice evaporative concentrate, fresh Morinda citrifolia whole fruit, dried Morinda citrifolia whole fruit, solvent extracted form Morinda citrif Morinda citrifolia seed treated with enzyme, Morinda citrifolia seed treated with enzyme, whole Morinda citrifolia seed processed, Morinda citrifolia whole fruit, leaf extract, leaf juice, defatted Morinda citrifolia seed extract and untreated Morinda citrifolia 13. A food product according to claim 12, comprising a component selected from a list of seed extracts. Furthermore, glycosaminoglycan, hyaluronic acid, glucosamine HCl, glucosamine sulfate, chondroitin sulfate, essential amino acids, essential fatty acids, long chain fatty acids, omega-3 fatty acids, omega-6 fatty acids, macro minerals, micro minerals, peptide chains, branches Chain amino acids, all noni seeds, all fried noni seeds, all fried noni seeds, fried noni nonfat seeds, fried noni seeds, fried noni seeds, fried ground noni seeds, Of roasted and ground noni defatted seeds, roasted and flakes of noni defatted seeds, roasted and flakes of noni seeds, roasted and extruded noni defatted seeds, and roasted and extruded noni of noni 13. A food product according to claim 12, comprising an ingredient selected from a list of seeds. Furthermore, quercetin, rutin, scopoletin, octoate, potassium, vitamin C, terpenoid, alkaloid, anthraquinone, nordamanacantal, molindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycoside, linoleic acid, alizarin, amino acid, 13. The formulation of claim 12, comprising an active ingredient selected from the group comprising akbin, L-asperloside, caproic acid, caprylic acid, ursolic acid, and putative prozeroin. 17. The food product of claim 16, wherein the quercetin is present in an amount of about 0.1-10% by weight. 17. The food product of claim 16, wherein the rutin is present in an amount of about 0.1-10% by weight. A method of feeding animals,
Add the processed Morinda citrifolia product to the alcoholic solution;
Isolating and extracting the active ingredient of the processed Morinda citrifolia product from the solution;
Mixing the extracted active ingredient with other food ingredients; and feeding the animal with the food
The method including each process of these. 20. The method of claim 19, wherein the processed Morinda citrifolia product comprises processed Morinda citrifolia fruit juice. 20. The method of claim 19, wherein the processed Morinda citrifolia product comprises processed Morinda citrifolia puree. 20. The method of claim 19, wherein the alcoholic solution is selected from the group consisting essentially of methanol, ethanol, and ethyl acetate, and other alcoholic derivatives. 20. The method of claim 19, wherein the active ingredient is quercetin. 24. The method of claim 23, wherein the active ingredient is rutin that acts synergistically with the quercetin.